In this article, we will discuss the 10 Best NASDAQ Growth Stocks to Buy and Hold Forever.

On April 15, Kim Bolton, President & Portfolio Manager at Black Swan Dexteritas, appeared on BNN Bloomberg to share his outlook on Technology Stocks.  Talking about how the Iran conflict over the last six weeks impacted the market’s trajectory, Bolton suggested that the market serves as a future predictor and has effectively pushed those concerns aside. He observed that investors seem to view the conflict as being in the rear-view mirror, shifting their focus back toward earnings season and the AI bandwagon. While tech lagged for much of the year, Fernandez notes that Nvidia recently climbed back toward the $200 mark, which it had not reached in a long time.

Bolton addressed the recent lagging of the tech sector by clarifying that he does not see a general rotation from growth into value. Instead, he believes that there has been a specific rotation within the tech industry. Investors have taken profits from pick-and-shovel companies (those building the AI infrastructure) and reallocated that capital into end-users who are successfully employing and embedding AI into their operations. He pointed out that this shift is already yielding results in the financial sector, where big US banks are reporting increased productivity and revenue generation from AI. He also sees this maturing AI stack benefiting healthcare, retail, and logistics.

Our Methodology

We used screeners to identify stocks that have a track record of delivering earnings growth and have grown their EPS by at least 20% over the past 3 years, and are expected to grow their earnings by at least 25% over the next 5 years. We limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.

Note: All data was sourced on April 23. 

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

10 Best NASDAQ Growth Stocks to Buy and Hold Forever

10. HeartBeam Inc. (NASDAQ:BEAT)

HeartBeam Inc. (NASDAQ:BEAT) is one of the best NASDAQ growth stocks to buy and hold forever. On April 14, HeartBeam announced the pricing of a $10 million underwritten public offering, consisting of 12,500,000 shares of common stock. The offering is notably led by the company’s first commercial customer, ClearCardio, alongside HeartBeam’s executive leadership, board members, and existing institutional investors. Underwriters have also been granted a 30-day option to purchase up to an additional 1,875,000 shares to cover over-allotments.

The company plans to use the net proceeds to fund several key strategic initiatives, including the commercialization of its FDA-cleared 12-lead synthesized ECG system. Additionally, the capital will support the development of an extended-wear patch, heart attack detection technology, and the enhancement of HeartBeam’s AI capabilities. These efforts are aimed at expanding the reach of the company’s cardiac monitoring platform and providing more accessible insights for patients and providers.

CEO Robert Eno emphasized that the participation of ClearCardio as an investor serves as a validation of HeartBeam Inc.’s (NASDAQ:BEAT) technology, particularly within the preventive cardiology and concierge healthcare markets. The financing provides the necessary working capital to support general corporate purposes and meet the growing demand for data-driven cardiac care.

HeartBeam Inc. (NASDAQ:BEAT) is a medical technology company specializing in 3D, credit-card-sized ECG solutions for remote cardiac monitoring. Its HeartBeam System enables high-fidelity arrhythmia and heart attack detection outside of clinical settings using portable hardware and cloud-based algorithms.

9. Cingulate Inc. (NASDAQ:CING)

Cingulate Inc. (NASDAQ:CING) is one of the best NASDAQ growth stocks to buy and hold forever. On March 18, Cingulate reported its financial results for Q4 and the full year 2025, highlighting the recent acceptance of an NDA for its lead ADHD candidate, CTx-1301. The company also announced a strengthened intellectual property portfolio, including a US Patent Notice of Allowance and additional grants in Europe for CTx-1301. These legal milestones recognize the unique capabilities of Cingulate’s proprietary Precision Timed Release/PTR platform, which is designed to deliver medication according to specific patient needs throughout the day.

Furthermore, the company recently closed a $12 million private placement at-the-market pricing to support its foundation. The CEO noted that this funding, combined with the addition of experienced commercial leadership, supports the company’s transition toward market readiness. While advancing through the FDA regulatory review process for CTx-1301, Cingulate is focusing on manufacturing scale-up to ensure it is positioned for a successful commercial launch upon potential approval.

The company’s strategy remains centered on using its PTR platform to develop a pipeline of next-gen products that address unmet needs in the biopharma space. The CEO emphasized that the progress made throughout 2025 has set a strong trajectory for 2026, with a focus on building long-term value for shareholders and patients alike. By securing its patent estate and strengthening its balance sheet, Cingulate Inc. (NASDAQ:CING) aims to provide a different treatment option for the ADHD market.

Cingulate Inc. (NASDAQ:CING) is a clinical-stage biotech company using its proprietary drug delivery platform to develop treatments for ADHD and anxiety. Its lead candidate, CTx-1301, is in Phase 3 trials for ADHD across all age groups, while its pipeline includes CTx-2103 for anxiety and plans for CTx-1302 to further address ADHD.